Ashley Yeo

Ashley Yeo

Executive Editor, MTI; Medtech Editor, In Vivo

London, UK

Ashley has reported on health care market issues with Citleline and legacy companies since 1988, initially as a linguist on the France and Germany desk and later becoming editor of three titles. Two publications are his current focus for written and multimedia (panel moderating and podcasts) content: In Vivo (global medtech market access); and Medtech Insight (regulation and policy content for the UK, European and Asia markets).

Latest from Ashley Yeo

Industry Gives Broad Welcome To Abolition Of NHS England But Needs Time To Weigh Impact

Insight into the knock-on effects on innovation adoption and procurement is keenly awaited by medtechs.

Reinventing Prevention: Milken Institute Foresees Another Route Using Private And Public Funding

New funding mechanisms are required to give more momentum to prevention in the community and thereby relieve pressure on overburdened health care providers like the UK National Health Service. So says Simon Radford, a director at global thinktank the Milken Institute, which sees a solution in more funding for community-level prevention.

Prevention And Deregulation Likely To Be Central In German Coalition’s Healthcare Plan

Germany’s Union parties may have little alternative than to bring the SPD into a new four-year coalition, says Clifford Chance partner and life sciences legal expert Gunnar Sachs. Health policy will likely see both textural and structural changes.

UK MHRA Holds 2025 Device Registration Fee Increase

Most fees and fee uplifts proposed by the UK MHRA to begin in April 2025 will be implemented on schedule. A general 8.85% increase will be applied to all statutory fees, but the new medical devices registration fee is subject to ongoing review and/or alternative options.

New German Coalition Expected To Prioritize Prevention And Healthcare Deregulation

Germany’s Union parties may have little alternative than to bring the SPD into a new four-year coalition, says Clifford Chance partner and life sciences legal expert Gunnar Sachs. Health policy will likely see both textural and structural changes.

Leadership Changes In UK Healthcare: Medtech Pledges To Work With New MHRA Chief Executive

Lawrence Tallon will succeed June Raine as MHRA chief executive on 1 April. UK medtechs will prioritize an early meeting with the man who since 2020 has served as deputy chief executive of Guy’s and St Thomas' NHS Trust.